PriceTargets.com logo

Odyssey Therapeutics - ODTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside: 88.68%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$16.96 As of 06/1/2026 05:00 PM ET
▼ -0.05 (-0.29%)

This chart shows the closing price for ODTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Odyssey Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ODTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ODTX

Analyst Price Target is $32.00
▲ +88.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Odyssey Therapeutics in the last 3 months. The average price target is $32.00, with a high forecast of $40.00 and a low forecast of $26.00. The average price target represents a 88.68% upside from the last price of $16.96.

This chart shows the closing price for ODTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Odyssey Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/2/2026Cantor FitzgeraldInitiated CoverageOverweight
6/2/2026TD CowenInitiated CoverageBuy
6/2/2026JPMorgan Chase & Co.Initiated CoverageOverweight$26.00
6/2/2026WedbushInitiated CoverageOutperform$30.00
6/2/2026OppenheimerInitiated CoverageOutperform$40.00
(Data available from 6/2/2021 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Odyssey Therapeutics

Read More

Today's Range

Now: $16.96
Low: $16.53
High: $18.15

50 Day Range

MA: N/A

52 Week Range

Now: $16.96
Low: $15.35
High: $20.30

Volume

127,382 shs

Average Volume

330,139 shs

Market Capitalization

$800.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Odyssey Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Odyssey Therapeutics in the last twelve months: Cantor Fitzgerald, Oppenheimer Holdings, Inc., TD Cowen, and Wall Street Zen.
View the latest analyst ratings for ODTX.

What is the current price target for Odyssey Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Odyssey Therapeutics in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 135.8%. Oppenheimer Holdings, Inc. has the highest price target set, predicting ODTX will reach $40.00 in the next twelve months. Oppenheimer Holdings, Inc. has the lowest price target set, forecasting a price of $40.00 for Odyssey Therapeutics in the next year.
View the latest price targets for ODTX.

What is the current consensus analyst rating for Odyssey Therapeutics?

Odyssey Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ODTX will outperform the market and that investors should add to their positions of Odyssey Therapeutics.
View the latest ratings for ODTX.